Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent Clostridioides difficile Infection in Older Adults With Underlying Comorbidities.
Glenn S TillotsonLaurie Archbald-PannoneStuart JohnsonSamson NgMasakazu AndoAdam HarveyLindy BanckePaul FeuerstadtPublished in: Open forum infectious diseases (2022)
RBX2660 is efficacious and safe in older adults with recurrent CDI and underlying comorbidities.